KEI Comments Regarding NIH Prospective Exclusive License to Georgetown University for Pancreatic Cancer Diagnostic

On April 28, 2022, Knowledge Ecology International (KEI) provided comments on the latest National Institutes of Health (NIH) Federal Register notice concerning licensing, the “Prospective Grant of an Exclusive Patent License: Development of Diagnostic for Imaging and Early Detection of… Continue Reading

Save the Date – 27 April 2022 – South Centre/KEI/PIJIP Workshop on the L&E work programme and the WIPO broadcasting treaty

On Wednesday, 27 April 2022 from 14:00 CEST to 16:00 CEST, the South Centre, Knowledge Ecology International (KEI), and the Washington College of Law’s Program on Information Justice and Intellectual Property (PIJIP) will convene a workshop to prepare for the… Continue Reading

Amicus Brief of Professor Brook Baker on the human right principles and TRIPS-compliant interpretation of the compulsory license petition filed by KEI in the Dominican Republic

Last week, Professor Brook Baker filed an Amicus Brief responding to four of the arguments made by Pfizer against the compulsory license requested by KEI in the Dominican Republic to allow the distribution of the generic version of Paxlovid. His… Continue Reading

Additional Comments for the Public Hearing on the Proposed WHO Treaty on Pandemic Preparedness and Response

These are the additional comments to the WHO Public Hearing on a possible WHO treaty or other instrument on pandemic preparedness and response (KEI also provided oral testimony at the hearing, and filed earlier comments here). Luis Gil Abinader –… Continue Reading

Pfizer’s March 18, 2022 opposition to the KEI request for a compulsory license in Dominican Republic for Paxlovid.

On March 18, 2022, Pfizer filed a 45 page opposition to the KEI application for a compulsory license on Paxlovid patents in the Dominican Republican. This is the Pfizer filing, and KEI’s unofficial translation. Pfizer-opposition-DR-CL-18March2022.pdf Translation-Pfizer-opposition-KEI-CL-Paxlovid-18march2022.pdf The December 3, 2021… Continue Reading

KEI Comments Regarding NIH Exclusive License to Syncopation for CAR T Therapy

Knowledge Ecology International (KEI) filed comments with the National Institutes of Health (NIH) on March 16, 2022 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor T-Cell Therapies (CAR-T) That are Specific to… Continue Reading